Time filter

Source Type

Dettori I.,Etablissement francais du sang Alpes Mediterranee EFSAM | Ladaique P.,Institute Paoli Calmettes IPC
Transfusion Clinique et Biologique

The platelet refractoriness is a complication of transfusion treatments potentially dramatic in onco-haematology. Chemo-treatment of haematological malignancies or packs of allogeneic bone marrow transplants require iterative platelet transfusion requirements. The discovery of a platelet refractoriness along with its support should be the most reactive as possible but also adapted to the cause. In the case of allo-immunization, it may be expected. The purpose of this presentation is to recall the different etiologies and perform a feedback on the support transfusion platelet of onco-haematology adult patients at Institut Paoli-Calmettes (IPC) in partnership with the EFSAM. © 2014. Source

Ferrera-Tourenc V.,Etablissement francais du sang Alpes Mediterranee EFSAM | Dettori I.,Etablissement francais du sang Alpes Mediterranee EFSAM | Chiaroni J.,Etablissement francais du sang Alpes Mediterranee EFSAM | Lassale B.,Assistance publique des Hopitaux de Marseille APHM Hemovigilance
Transfusion Clinique et Biologique

Introduction: Blood transfusion safety depends on strict compliance with each step of a process beginning with the order for labile blood products and related immunohematologic testing and ending with administration and follow-up of the receiver. This process is governed by stringent regulatory texts and guidelines. Despite precautions, processing errors are still reported. Analysis of incident reports shows that the most common cause involves patient identification and that most errors occur at two levels, i.e. the entry of patient information and management of multiple regulatory crosschecks and record-keeping using different systems. Method: The purpose of this report is to describe the collaborative approach implemented by the établissement français du Sang Alpes-Méditerranée (EFSAM) and the Assistance publique des Hôpitaux de Marseille (APHM) to secure the blood transfusion process and protect interfaces while simplifying and facilitating exchanges. Results: Close cooperation has had a threefold impact with simplification of administration, improvement of experience feedback, and better management of test ordering. The organization implemented between the two institutions has minimized document redundancy and interfaces between immunohematologic testing and delivery. Collaboration based on experience feedback has improved the level of quality and cost control. Conclusion: In the domain of blood transfusion safety, the threshold of 10-5 has been reached with regard to the risk of ABO errors in the distribution concentrated red cells (CRC). In addition, this collaborative organization has created further opportunity for improvement by deploying new methods to identify simplification measures and by controlling demand and usage. © 2013 Elsevier Masson SAS. Source

Discover hidden collaborations